Citalopram

DRUG INFORMATION

  ADULT
    - Use another citalopram product for initial dosage titration or dosages other than
      30 mg once daily.
      Source: US FDA label for citalopram (citalopram), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Recommended dosage of Citalopram Capsules is 30 mg once daily.
      Source: US FDA label for citalopram (citalopram), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Citalopram dosages above 40 mg once daily are not recommended due to the
      risk of QT prolongation.
      Source: US FDA label for citalopram (citalopram), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of citalopram have not been established in pediatric
      patients. Two placebo-controlled trials in 407 pediatric patients with MDD have
      been conducted with other another formulation of citalopram, and the data were not
      sufficient to support use in pediatric patients. Antidepressants increase the risk
      of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning ,
      Warnings and Precautions ( 5.1 )] .
      Source: US FDA label for citalopram (citalopram), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for citalopram (citalopram),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - ( 8.5 ) Hepatic Impairment: Not recommended.
      Source: US FDA label for citalopram (citalopram), section 'use in specific
      populations', retrieved 2026-08-29
    - SSRIs, including citalopram, have been associated with cases of clinically
      significant hyponatremia in elderly patients, who may be at greater risk for this
      adverse reaction [see Warnings and Precautions ( 5.9 )] . 8.6 Hepatic Impairment
      Citalopram Capsules is not recommended in patients with hepatic impairment.
      Source: US FDA label for citalopram (citalopram), section 'use in specific
      populations', retrieved 2026-08-29
    - Avoid use of Citalopram Capsules in CYP2C19 poor metabolizers, patients receiving
      concomitant cimetidine or another CYP2C19 inhibitor, patients with hepatic
      impairment, and patients who are greater than 60 years of age, because Citalopram
      Capsules are only available in a 30 mg dose strength and dosage adjustments are
      not possible [see Drug Interactions ( 7 ), Use in Specific Populations ( 8.5 , 8.6
      ), Clinical Pharmacology ( 12.3 )] .
      Source: US FDA label for citalopram (citalopram), section 'warnings and cautions',
      retrieved 2026-08-29

  PREGNANCY
    - Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors
      pregnancy outcomes in women exposed to antidepressants during pregnancy.
      Source: US FDA label for citalopram (citalopram), section 'pregnancy', retrieved
      2026-08-29
    - Healthcare providers are encouraged to register patients by calling the National
      Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at
      https://womensmentalhealth.org/research/pregnancyregistry/antidepressants.
      Source: US FDA label for citalopram (citalopram), section 'pregnancy', retrieved
      2026-08-29
    - Risk Summary Based on data from published observational studies, exposure to
      SSRIs, particularly in the month before delivery, has been associated with a less
      than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and
      Precautions ( 5.4 ) and Clinical Considerations] .
      Source: US FDA label for citalopram (citalopram), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Citalopram was administered orally to pregnant rats during late gestation and
      lactation periods at doses of 4.8, 12.8, and 32 mg/kg/day, which are approximately
      1, 3, and 8 times the MRHD of 40 mg, based on mg/m 2 body surface area.
      Source: US FDA label for citalopram (citalopram), section 'use in specific
      populations', retrieved 2026-08-29
    - In a separate study, similar effects on offspring mortality and growth were seen
      when dams were treated throughout gestation and early lactation at doses ≥ 24
      mg/kg/day, which is approximately 6 times the MRHD.
      Source: US FDA label for citalopram (citalopram), section 'use in specific
      populations', retrieved 2026-08-29
    - A NOAEL was not determined in that study. 8.2 Lactation Risk Summary Data from the
      published literature report the presence of citalopram in human milk at relative
      infant doses ranging between 0.7 to 9.4% of the maternal weight-adjusted dosage
      and a milk/plasma ratio ranging between 0.78 to 4.3.
      Source: US FDA label for citalopram (citalopram), section 'use in specific
      populations', retrieved 2026-08-29